The use of mycophenolate mofetil in transplant recipients.

[1]  C. Lavie,et al.  Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation. , 1998, The Journal of the Association of Physicians of India.

[2]  G. Tufveson,et al.  Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. , 1999, Transplantation.

[3]  B. Davidson,et al.  Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. , 1999, Transplantation.

[4]  S. Hamilton-Dutoit,et al.  Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. , 1999, Transplantation.

[5]  G. Dekan,et al.  Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  A. Matas,et al.  PREDNISONE WITHDRAWAL IN KIDNEY TRANSPLANT RECIPIENTS ON CSA/MMF- A PROSPECTIVE RANDOMIZED STUDY , 1999 .

[7]  D. Abramowicz,et al.  Preliminary results of a randomised, controlled study investigating the withdrawal of neoral in stable renal transplant recipients receiving mycophenolate mofetil in addition to neoral and steroids , 1999 .

[8]  W. Weimar,et al.  WITHDRAWAL OF CYCLOSPORINE OR PREDNISONE IN RENAL TRANSPLANT RECIPIENTS TREATED WITH MYCOPHENOLATE MOFETIL, CYCLOSPORINE, AND PREDNISONE: A RANDOMISED STUDY. , 1999 .

[9]  D. Renlund,et al.  Three-Year Allograft Vasculopathy Results of the Multicenter Heart Transplant Mycophenolate Mofetil Randomized Trial , 1999 .

[10]  J. Fink,et al.  CHRONIC ALLOGRAFT NEPHROPATHY: EFFECT OF CYCLOSPORINE REDUCTION AND ADDITION OF MYCOPHENOLATE ON PROGRESSION OF RENAL DISEASE. , 1999 .

[11]  J. Emond,et al.  Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. , 1999, Transplantation.

[12]  T. Starzl,et al.  A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. , 1999, Transplantation.

[13]  U. Settmacher,et al.  Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. , 1999, Transplantation proceedings.

[14]  J. Miller,et al.  Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. , 1999, Transplantation proceedings.

[15]  A. Tsaroucha,et al.  Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. , 1999, Therapeutic drug monitoring.

[16]  A. Melk,et al.  Rethinking chronic allograft nephropathy: the concept of accelerated senescence. , 1999, Journal of the American Society of Nephrology : JASN.

[17]  D. Serón,et al.  Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. , 1998, Transplantation.

[18]  S. Knechtle,et al.  A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. , 1998, Transplantation.

[19]  T. Starzl,et al.  A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. , 1998, The Journal of urology.

[20]  T. Starzl,et al.  A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. , 1998, Transplantation.

[21]  R. Merion,et al.  RANDOMIZED MULTICENTER OPEN LABEL COMPARATIVE TRIAL OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION , 1998 .

[22]  D. Renlund,et al.  A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. , 1998, Transplantation.

[23]  D. Sutherland,et al.  Mycophenolate mofetil in pancreas transplantation. , 1998, Transplantation.

[24]  S. Greenstein,et al.  Chronic renal allograft rejection: no response to mycophenolate mofetil. , 1998, Transplantation.

[25]  M. Levine,et al.  Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  B. Zanker,et al.  Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. , 1998, Transplantation.

[27]  T. Mathew.  A Blinded, Long-term, Randomized Multicenter Study Of Mycophenolate Mofetil In Cadaveric Renal Transplantation: Results at Three Years1,2 , 1998 .

[28]  C. Billerey,et al.  Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report. , 1998, Transplantation.

[29]  R. Mendez.  FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. , 1998, Transplantation proceedings.

[30]  G. Staehler,et al.  Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. , 1998, Transplantation proceedings.

[31]  G. Danovitch,et al.  Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. , 1998, Transplantation proceedings.

[32]  E. Woodle,et al.  Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. , 1998, Transplantation proceedings.

[33]  W. Weimar,et al.  A RANDOMISED STUDY OF CONVENTIONAL VS LOW DOSE CYCLOSPORINE IN RENAL TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINE, MYCOPHENOLATE MOFETIL AND PREDNISONE. , 1998 .

[34]  G. Morris-Stiff,et al.  Single centre experience with mycophenolate mofetil for refractory rejection in cadaveric renal transplantation , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[35]  A. Mimran,et al.  Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. , 1998, Transplantation.

[36]  P. Halloran,et al.  Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion. , 1998, Transplant immunology.

[37]  E. De Clercq,et al.  The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo , 1998, Antimicrobial Agents and Chemotherapy.

[38]  M. Pescovitz,et al.  Mycophenolate mofetil for the treatment of a first acute renal allograft rejection , 1998 .

[39]  M. Wiesel,et al.  A PLACEBO CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL USED IN COMBINATION WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR THE PREVENTION OF ACUTE REJECTION IN RENAL ALLOGRAFT RECIPIENTS: 1-YEAR RESULTS , 1998 .

[40]  M. Stegall,et al.  Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. , 1997, Transplantation.

[41]  M. Stegall,et al.  Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. , 1997, Transplantation.

[42]  P. Neuhaus,et al.  FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. , 1997, Transplantation proceedings.

[43]  A. Tsaroucha,et al.  Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. , 1997, Transplantation proceedings.

[44]  F. Martinez,et al.  Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. , 1997, The Annals of thoracic surgery.

[45]  L. Garrison,et al.  The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1997, Journal of the American Society of Nephrology : JASN.

[46]  A. Tsaroucha,et al.  Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. , 1997, Transplant immunology.

[47]  A. Tsaroucha,et al.  Mycophenolate mofetil rescue therapy in liver transplant recipients. , 1997, Transplantation proceedings.

[48]  T. Starzl,et al.  Tacrolimus rescue therapy for renal allograft rejection--five-year experience. , 1997, Transplantation.

[49]  P. Halloran,et al.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. , 1997, Transplantation.

[50]  R. Wiesner,et al.  A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. , 1996, Transplantation.

[51]  P. Ratcliffe,et al.  Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression , 1996, The Lancet.

[52]  Mark A. Murcko,et al.  Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid , 1996, Cell.

[53]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[54]  M. Hale,et al.  Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration , 1996, Journal of clinical pharmacology.

[55]  M. Pescovitz,et al.  Rescue therapy with mycophenolate mofetil , 1996 .

[56]  Sanders Ce,et al.  Role of hypertension in chronic renal allograft dysfunction. , 1995 .

[57]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[58]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[59]  Y. Vanrenterghem.  Acute rejection and renal allograft outcome. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[60]  C. Young,et al.  RS-61443: a new immunosuppressive agent. , 1994, Transplantation proceedings.

[61]  D. Naimark,et al.  Determinants of long-term renal allograft survival , 1994 .

[62]  D. Renlund,et al.  Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[63]  C. White-Williams,et al.  Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[64]  W. Payne,et al.  THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2 , 1994, Transplantation.

[65]  E. Kieff,et al.  Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes , 1994, Antimicrobial Agents and Chemotherapy.

[66]  A. Matas,et al.  Steroid-related complications in the cyclosporine era. , 1994, Clinical transplantation.

[67]  G Opelz,et al.  Feeding the preterm infant , 1993, The Lancet.

[68]  Y. Natsumeda,et al.  Human Type I and II IMP Dehydrogenases as Drug Targets , 1993, Annals of the New York Academy of Sciences.

[69]  S. Ohlman,et al.  THE IMPACT OF ACUTE REJECTION EPISODES ON LONG‐TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENS , 1993, Transplantation.

[70]  D. Renlund,et al.  THE USE OF MYCOPHENOLATE MOFETIL (RS‐61443) IN HUMAN HEART TRANSPLANT RECIPIENTS , 1993, Transplantation.

[71]  A. Allison,et al.  Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. , 1993, Transplantation proceedings.

[72]  D. Dunn,et al.  Early versus late acute renal allograft rejection: impact on chronic rejection. , 1993 .

[73]  D. Dunn,et al.  Risk factors for chronic rejection in renal allograft recipients. , 1993, Transplantation.

[74]  H. Sollinger,et al.  One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. , 1993, Transplantation proceedings.

[75]  A. Allison,et al.  Mycophenolate mofetil, a rationally designed immunosuppresive drug , 1993 .

[76]  M. Henry,et al.  Predictors of long-term primary cadeveric renal transplant survival , 1993 .

[77]  G. Klintmalm,et al.  RS-61443 for treatment-resistant human liver rejection. , 1993, Transplantation proceedings.

[78]  L. Lasky,et al.  Selectins: interpreters of cell-specific carbohydrate information during inflammation. , 1992, Science.

[79]  G. Klintmalm,et al.  RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection , 1992, Annals of surgery.

[80]  Sinclair Nr.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. , 1992 .

[81]  H. Sollinger,et al.  RS‐61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1 , 1992, Transplantation.

[82]  P. Belitsky,et al.  THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTS , 1992, Transplantation.

[83]  P. Terasaki,et al.  ANALYSES OF THE UNOS SCIENTIFIC RENAL TRANSPLANT REGISTRY AT THREE YEARS—EARLY EVENTS AFFECTING TRANSPLANT SUCCESS1–3 , 1992, Transplantation.

[84]  N. Sinclair,et al.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[85]  S. Korsmeyer,et al.  Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. , 1992, Annual review of immunology.

[86]  D. Dunn,et al.  Causes of Renal Allograft Loss: Progress in the 1980s, Challenges for the 1990s , 1991, Annals of surgery.

[87]  W. Bechstein,et al.  RS-61443 reverses acute allograft rejection in dogs. , 1991, Surgery.

[88]  T. Springer,et al.  Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins , 1991, Cell.

[89]  Cecka Jm.  Early rejection: determining the fate of renal transplants. , 1991 .

[90]  A. Allison,et al.  Lymphocyte‐Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion , 1991, Scandinavian journal of immunology.

[91]  A. Allison,et al.  Lymphocyte‐Selective Antiproliferative and Immunosuppressive Effects of Mycophenolic Acid in Mice , 1991, Scandinavian journal of immunology.

[92]  H. Sollinger,et al.  RS-61443 : mechanism of action, experimental and early clinical results , 1991 .

[93]  D. Eckhoff,et al.  RS-61443--a new, potent immunosuppressive agent. , 1991, Transplantation.

[94]  A. Allison,et al.  Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. , 1990, Transplantation proceedings.

[95]  S. Albelda,et al.  Integrins and other cell adhesion molecules , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[96]  M. Foegh.  Chronic rejection--graft arteriosclerosis. , 1990, Transplantation proceedings.

[97]  J. Trowsdale,et al.  Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells , 1989, Nature.

[98]  G. Klein,et al.  How one thing has led to another. , 1989, Annual review of immunology.

[99]  A. Rickinson,et al.  Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein- Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance , 1988, The Journal of experimental medicine.

[100]  I. Penn.  Tumors of the immunocompromised patient. , 1988, Annual review of medicine.

[101]  M. Greist,et al.  Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. , 1987, Journal of the American Academy of Dermatology.

[102]  R. Luke,et al.  CYCLOSPORIN IN THERAPEUTIC DOSES INCREASES RENAL ALLOGRAFT VASCULAR RESISTANCE , 1986, The Lancet.

[103]  L. Miller,et al.  HEART GRAFT ARTERIOSCLEROSIS: AN OMINOUS FINDING ON ENDOMYOCARDIAL BIOPSY , 1985, Transplantation.

[104]  M. Epstein,et al.  T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. , 1984, Cellular immunology.

[105]  H. Balfour,et al.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. , 1983, Annals of surgery.

[106]  C. Ross.  Biosynthesis of Nucleotides , 1981 .

[107]  S. Kornfeld,et al.  Structure of Glycoproteins and Their Oligosaccharide Units , 1980 .

[108]  P. Reichard,et al.  Reduction of ribonucleotides. , 1979, Annual review of biochemistry.

[109]  H. Roenigk,et al.  Mycophenolic acid for psoriasis. , 1977, Archives of dermatology.

[110]  A. Allison,et al.  Control of phosphoribosylpyrophosphate synthesis in human lymphocytes. , 1977, Biochemical and biophysical research communications.

[111]  R. Fleischmajer,et al.  Mycophenolic acid in the treatment of psoriasis: long-term administration. , 1977, Archives of dermatology.

[112]  R. Watts,et al.  The role of de novo purine synthesis in lymphocyte transformation. , 1977, Ciba Foundation symposium.

[113]  R. Watts,et al.  IMMUNOLOGICAL OBSERVATIONS ON PATENTS WITH LESCH-NYHAN SYNDROME, AND ON THE ROLE OF DE-NOVO PURINE SYNTHESIS IN LYMPHOCYTE TRANSFORMATION , 1975, The Lancet.

[114]  P. Frost,et al.  Treatment of psoriasis with oral mycophenolic acid. , 1975, The Journal of investigative dermatology.

[115]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[116]  M. Esterman,et al.  Metabolism and biochemistry of mycophenolic acid. , 1972, Cancer research.

[117]  N. Nissen,et al.  Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. , 1972, Cancer chemotherapy reports.

[118]  I. Todd,et al.  Mycophenolic acid (NSC-129185): preliminary clinical trials. , 1972, Cancer chemotherapy reports.

[119]  S. Suzuki,et al.  Immunosuppressive effect of mycophenolic acid. , 1969, The Journal of antibiotics.

[120]  S. Carter,et al.  Mycophenolic Acid: an Anti-cancer Compound with Unusual Properties , 1969, Nature.

[121]  G. Tamura,et al.  Antitumor activity of mycophenolic acid. , 1969, The Journal of antibiotics.

[122]  T. Franklin,et al.  The inhibition of nucleic acid synthesis by mycophenolic acid. , 1969, The Biochemical journal.

[123]  R. H. Williams,et al.  Mycophenolic acid: antiviral and antitumor properties. , 1968, The Journal of antibiotics.

[124]  A. Sanders,et al.  Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx. , 1946, Lancet.

[125]  Collyer,et al.  THE LANCET.: SUNDAY, OCTOBER 12, 1823 , 1823 .